AbbVie ABBV announced that the European Commission has granted marketing approval to its blockbuster drug Rinvoq for treating giant cell arteritis (“GCA”), an autoimmune disease that causes ...

Rinvoq (upadacitinib) is a prescription drug that works to treat certain inflammatory conditions by decreasing the activity of immune system cells. Your response to this drug may vary based on ...

AbbVie today announced that the European Commission (EC) granted marketing authorization to RINVOQ® (upadacitinib; 15 mg, once daily) for the treatment of giant cell arteritis (GCA) in adult patients.

AbbVie has picked up another indication for its JAK inhibitor Rinvoq in the EU, becoming the first approved oral therapy for giant cell arteritis (GCA), an autoimmune disease affecting the arteries.

Discover AbbVie's strong performance, with immunology growth and undervaluation despite challenges. Click here to read an ...

RINVOQ is the first and only oral Janus kinase (JAK) inhibitor approved in the European Union (EU) to treat adult patients with giant cell arteritis (GCA) The approval is supported by data from ...

AbbVie claimed FDA approval for its JAK inhibitor Rinvoq (upadacitinib) for rheumatoid arthritis on Friday, setting its price just a little below that of its antibody blockbuster Humira.